Glaukos Corporation announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020. Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 million in Glaucoma net sales and approximately $15 million in Corneal Health net sales. Preliminary and unaudited total net sales for the full year of 2020 are expected to be approximately $225 million, consisting of approximately $179 million in Glaucoma net sales and approximately $46 million in Corneal Health net sales.